- Research article
- Open Access
Impact of animal strain on gene expression in a rat model of acute cardiac rejection
- Katherine J Deans†1, 4, 6,
- Peter C Minneci†1, 4, 5,
- Hao Chen1,
- Steven J Kern1,
- Carolea Logun1,
- Sara Alsaaty1,
- Kelly J Norsworthy1,
- Stephanie M Theel1,
- Joel D Sennesh3,
- Jennifer J Barb2,
- Peter J Munson2,
- Robert L Danner1 and
- Michael A Solomon1, 6Email author
© Deans et al; licensee BioMed Central Ltd. 2009
- Received: 18 February 2009
- Accepted: 24 June 2009
- Published: 24 June 2009
The expression levels of many genes show wide natural variation among strains or populations. This study investigated the potential for animal strain-related genotypic differences to confound gene expression profiles in acute cellular rejection (ACR). Using a rat heart transplant model and 2 different rat strains (Dark Agouti, and Brown Norway), microarrays were performed on native hearts, transplanted hearts, and peripheral blood mononuclear cells (PBMC).
In heart tissue, strain alone affected the expression of only 33 probesets while rejection affected the expression of 1368 probesets (FDR 10% and FC ≥ 3). Only 13 genes were affected by both strain and rejection, which was < 1% (13/1368) of all probesets differentially expressed in ACR. However, for PBMC, strain alone affected 265 probesets (FDR 10% and FC ≥ 3) and the addition of ACR had little further effect. Pathway analysis of these differentially expressed strain effect genes connected them with immune response, cell motility and cell death, functional themes that overlap with those related to ACR. After accounting for animal strain, additional analysis identified 30 PBMC candidate genes potentially associated with ACR.
In ACR, genetic background has a large impact on the transcriptome of immune cells, but not heart tissue. Gene expression studies of ACR should avoid study designs that require cross strain comparisons between leukocytes.
- Peripheral Blood Mononuclear Cell
- Heart Tissue
- Strain Effect
- Acute Cellular Rejection
- Dark Agouti
Acute cellular rejection (ACR) is a major cause of morbidity and mortality among cardiac transplant patients [1–3]. Prompt diagnosis with early intervention by appropriate adjustment of immunosuppressive medications can reverse ACR, while delayed treatment of ACR can lead to graft injury or loss. Conversely, unnecessary escalation of immunosuppression exposes patients to an increased risk of infections that can also be life-threatening . Unfortunately, symptoms and signs of ACR are often nonspecific. Diagnosis relies on serial cardiac biopsies, an invasive and costly procedure. In addition, ACR in its early stages can be a patchy process such that histopathologic examination of heart tissue can both under- and over-diagnose its presence [5, 6]. Noninvasive, sensitive, and specific tests that reliably detect ACR in its earliest stages would greatly simplify the management of cardiac transplant patients, increase graft survival, and improve clinical outcomes. These issues combined with the advent of high-throughput functional genomic and proteomic methodologies have fueled a search for ACR biomarkers, as well as new therapeutic targets.
To date, clinical studies have not convincingly identified ACR biomarkers that appear suitable for diagnostic testing across diverse patient populations . Observational gene discovery studies have been performed in ACR . However, proposed panels based on gene expression changes in blood lack biological plausibility and independent replication . Background noise from genotypic heterogeneity may have hampered these investigations. Proof of principle experiments using animal models of ACR that impose uniformity not achievable in clinical studies have also attempted to find candidate biomarkers. However, many of these studies have directly compared cells and tissues that originated from different animal strains [9–14]. Underlying genotypic differences have the potential to confound these experiments and lead to erroneous conclusions. Furthermore, this source of error is compounded and magnified in high-dimension, discovery-driven platforms such as microarrays that measure thousands of endpoints.
Natural variation in gene expression is known to be extensive across human populations [15–18] and animal strains [19–22]. Depending on the tissue and mouse strains examined, genotypic background appears to significantly affect the expression of 1 to 2% of the entire transcriptome [20–22]. These studies raise legitimate concerns about our ability to distinguish signal (phenotype of interest) from noise (heterogeneity or strain effects) in biomarker discovery studies. While genetic background can potentially influence the results of any study, animal investigations that require the use of more than one strain are at particular risk. Strain differences in animals and heterogeneity across human populations may significantly influence the transcriptomes of individuals to the extent that phenotypic differences of interest such as non-rejecting versus rejecting may be difficult or impossible to detect.
To date, the impact of strain differences or in essence genotypic heterogeneity on transcriptomic profiling has not been investigated in animal models of organ transplantation. Moreover, strain effects have not been quantified in tissues of interest nor have differences been thematically analyzed to determine whether study interpretation might be jeopardized. Here, the potential confounding effects of animal strain differences on expression profiling was examined in a heterotopic rat heart transplant model. RNA from native hearts, transplanted hearts, and peripheral blood mononuclear cells (PBMC) from normal and transplanted animals were interrogated using high-density oligonucleotide microarrays and analyzed for effects attributable to animal strain as well as rejection. Understanding the impact of genotypic heterogeneity on transcriptomic profiles is likely to improve experimental designs, increasing scientific accuracy for identifying promising biomarkers.
The protocol described in the current study was approved by the Animal Care and Use Committee (ACUC) of the Clinical Center of the National Institutes of Health (NIH). Animal care followed the criteria of the ACUC of the Clinical Center of the NIH.
All specimens were processed for histopathology using hematoxylin and eosin staining. Histological changes were blindly assessed by a pathologist, using the International Society for Heart and Lung Transplantation (ISHLT) grading system for rejection [23, 24].
Heterotopic Cardiac Transplantation
Fourteen cardiac transplantations (9 isogeneic and 5 allogeneic) were performed using a modified version of the heterotopic cardiac transplantation model reported by Yokoyama et al . Briefly, after heparinization, donor hearts were procured from Dark Agouti (DA) animals, flushed with Lactated Ringers, and prepared for transplantation with ligation of pulmonary vessels, creation of an atrial septal defect and disruption of the tricuspid valve leaflets via a right atriotomy. In isogeneic transplants, the recipient animal strain was Dark Agouti (DA to DA), and in allogeneic transplants the recipient animal strain was Brown Norway (DA to BN). In this model, the animal strains have major antigen mismatches and allografts lose pulsatility on post-transplant day 6 with histologic ISHLT grade 3R rejection. Heterotopic transplantation was performed by anastomosis of the donor ascending aorta to the recipient abdominal aorta and the donor right atrium to the recipient inferior vena cava using microsurgical techniques. Upon re-establishment of blood flow, all transplanted hearts resumed spontaneous contractions, had coordinated atrioventricular activity, and were free of gross surgical injury at the time of closure.
PBMC were isolated using the Nycoprep density gradient (Axis-Shield, Oslo, Norway). A cell count and differential were performed on all samples. Total RNA was prepared from PBMC using the RNeasy Mini kit with DNase treatment (Qiagen Inc., Valencia, CA). For PBMC, messageAmp II aRNA kit (Ambion Inc.) was used to process total RNA to cDNA and cRNA. Total RNA from heart tissue was prepared using RNeasy Mini kits with DNAase and Proteinase K treatment (Qiagen Inc). For heart tissue, total RNA (10 μg) was reverse transcribed using the SuperScript II Custom kit (Invitrogen, Carlsbad, CA). cDNA cleanup was performed using cDNA Sample Cleanup modules (Affymetrix, Santa Clara, CA). cDNA (1 μg) was used as a template for in vitro transcription and biotin labeling reaction using a BioArray High Yield kit (Enzo Life Sciences, Farmingdale, NY). cRNA cleanup was performed using cRNA Sample Cleanup modules (Affymetrix).
Fragmentation and hybridization was performed according to Affymetrix standard methodology. The Affymetrix RAE230A and RAE230 2.0 microarray chips were used for heart tissue samples and PBMC respectively. Microarrays were washed and stained using the standard format for the Affymetrix Fluidics Station (Affymetrix). The probe arrays were scanned using the Affymetrix Scanner G-3000. GeneChip Operating System (GSOS; Affymetrix) was used to quantify gene expression. Result quality was assessed by comparison to historical values for this laboratory.
TaqMan® (ABI, Rockville, MD) quantitative real time – polymerase chain reaction (qRT-PCR) was utilized to quantify mRNA levels. Sufficient total RNA was available from the PBMC preparations of 3 isogeneic transplants, 3 allogeneic transplants and 5 untransplanted rats. Gene specific probes and PCR primers for glyceraldehyde 3-phosphate dehydrogenase (GAPDH), chemokine (c-c motif) ligand 9 (Ccl9), integrin alpha L (Itgal), s100 calcium binding protein A9 (S100a9), granzyme B (Gzmb), pancreatic trypsin 1 (Prss1), and lectin galactose binding soluble 5 (Lgals5) were purchased from ABI (Foster City, CA). The High-capacity cDNA Archive kit (ABI, Foster City, CA) was used to prepare cDNA from 2 μg of total RNA. Resulting cDNA was used for qRT-PCR in triplicate according to the standard ABI protocol. The target mRNA of Ccl9, Itgal, S100a9, Gzmb, Prss1 and Lgals5 were normalized to GAPDH. Relative mRNA amounts were calculated as previously described . Final results were expressed as fold change.
Oligonucleotide Microarray Data Analysis
Output from Affymetrix GCOS (Gene Chip Operating Software, Affymetrix, Inc. Santa Clara, CA) was stored in the NIHGCOS database. Affymetrix signal intensities were retrieved and assembled for further statistical analysis using MSCL Analysts Toolbox , a microarray analysis package that uses custom written scripts for JMP (SAS Institute, Cary, NC). Signal intensities were normalized to median values and log transformed. The data discussed in this publication have been deposited in the National Center for Biotechnology Information's (NCBI) Gene Expression Omnibus (GEO)  and are accessible through GEO series accession number GSE6342 .
Principal component analysis (PCA), a tool for visualizing a multivariate response, was performed on the entire gene chip and is used to illustrate differences between various groups. The significance of individual principal components (PC) was calculated by numerical simulation using a program written with Matlab (Mathworks, Inc., Natick, MA). The program calculates a PCA for simulated random data 1000 times, retaining the percentage of variance explained by the first PC. If the percentage variance explained by the first PC of the actual data is larger than 95% of the values obtained for random data, this PC is considered significantly large at the p ≤ 0.05 level. The second PC is tested similarly, by considering the percentage of remaining variance explained, and comparing it to the comparable value for random data. The first two principal components (PC) were visualized in two-dimensional plots (PC1 vs. PC2).
Differences in heart tissue gene expression and differences in PBMC gene expression were assessed by ANOVA. A false discovery rate (FDR) of 10% , a present call (Pcall) of at least 50% in either of the two groups being compared, and a fold change (FC) of at least 3 was required to declare a probeset as differentially expressed. In heart tissue, strain effect was defined in native hearts as the log-ratio of expression levels of native hearts (BN) from allogeneic transplants to that of native hearts (DA) from isogeneic transplants. Rejection effect was defined in transplanted hearts as the log-ratio of allografts (DA) to isografts (DA) expression levels. Probesets manifesting differential expression attributable to strain, rejection, or both were then identified for heart tissue [Additional file 1]. For example, if all 3 criteria (FDR ≤ 10%, FC ≥ 3, Pcall ≥ 50% in either group being compared) were met for the native heart log-ratio, but not for the transplanted heart log-ratio then the differential expression for that probeset would be considered attributable to strain. In PBMC, the strain effect was defined by the log-ratio of expression levels for untransplanted BN rats over untransplanted DA rats. Due to the requirements of the experimental design (transplanted hearts were always of strain DA) the rejection effect in PBMC could not be separately measured (isogeneic transplants were hosted by DA rats and allogeneic transplants were hosted by BN rats). Therefore, in transplanted animals, the combined strain plus rejection effects were defined in PBMC as the log-ratio of expression levels for allograft recipients (BN) over isograft recipients (DA). Thus, probesets manifesting differential expression attributable to strain in untransplanted animals, strain plus rejection in transplanted animals or both were identified for PBMC [Additional file 2]. For example, in PBMC, if all 3 criteria (FDR ≤ 10%, FC ≥ 3, Pcall ≥ 50% in either group being compared) were met for the untransplanted log-ratio, but not for the transplanted log-ratio then the differential expression for that probeset would be considered attributable to strain.
Candidate genes induced by acute cellular rejection relative to the strain effect in peripheral blood mononuclear cells
Strain+Rejection Effect FC
Strain Effect FC
Strain+Rejection /Strain FC
ring finger protein (C3H2C3 type) 6 (predicted)
membrane-spanning 4-domains, subfamily A, member 7 (predicted)
S100 calcium binding protein A9 (calgranulin B)
complement component 1, q subcomponent, gamma polypeptide
distrobrevin binding protein 1
matrix metallopeptidase 14 (membrane-inserted)
Thyroid hormone receptor associated protein 6 (predicted)
myxovirus (influenza virus) resistance 2
prolylcarboxypeptidase (angiotensinase C) (predicted)
2',5'-oligoadenylate synthetase 1, 40/46 kDa
high mobility group box 1
COX15 homolog, cytochrome c oxidase assembly protein (yeast)
RT1 class II, locus Ba
complement factor B
interferon induced transmembrane protein 3
interferon-induced protein with tetratricopeptide repeats 3
Candidate genes suppressed by acute cellular rejection relative to the strain effect in peripheral blood mononuclear cells
Strain+Rejection Effect FC
Strain Effect FC
Strain+Rejection /Strain FC
similar to Glycophorin
pancreatic trypsin 1
similar to RIKEN cDNA 1110063G11 (predicted)
transcription factor Dp 2 (predicted)
Translocase of inner mitochondrial membrane 9 homolog (yeast)
lectin, galactose binding, soluble 5
immunoglobulin heavy chain 1a (serum IgG2a)
selenium binding protein 2
unc-5 homolog C (C. elegans)
Gene lists were analyzed with Ingenuity® Systems Pathway Analysis (Ingenuity® Systems, Redwood City, California)  and with the Database for Annotation, Visualization and Integrated Discovery (DAVID; NIAID, NIH) . Comparative analyses for enrichment of canonical pathways, Gene Ontology terms and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways were performed between each pair of lists. Each test of enrichment is a two-sided Fisher's exact test.
Hematoxylin and eosin stains were performed on transplanted hearts procured on post-transplant day 6. Allografts were characterized by diffuse inflammation and necrosis consistent with ISHLT grade 3 R. Isografts exhibited minimal histological changes consistent with ISHLT grade 0 R.
A Principal Component Analysis of Microarray Results
In contrast to heart tissue, PBMC, which are mostly T-lymphocytes, displayed a gene expression pattern dominated by strain effects that obscured any contribution from cardiac rejection. An initial analysis comparing animals with rejection (allograft recipients; BN rats) to those without rejection (isograft recipients; DA rats) indicated broad differences in gene expression and the possibility of multiple, strong biomarkers that could distinguish these phenotypes (Figure 2B). Allograft and isograft recipients separated clearly from each other along the PC1 axis. However, the addition of untransplanted animals to this analysis revealed that these transcriptomic differences were almost entirely attributable to rat strain rather than cardiac rejection. Note that expression profiles from untransplanted BN and DA rats similarly separate from each other along the PC1 axis (17% of the experimental variability; p < 0.05). These untransplanted rats grouped closely with their respective strain of transplanted rats whether or not the animals had ACR (Figure 2B). PC2 was not significant and did not further resolve these groups.
Strain Effects on the Expression Profiles of Heart Tissue and PBMC in ACR
Strain Effects on Pathways and Networks Potentially Relevant to ACR Pathogenesis
Genes Associated with ACR in PBMC
Of the 30 candidate genes, 22 could be mapped to homologous human genes. These 22 homologues were compared against a list of 97 uniquely named genes compiled from 3 human studies investigating differential PBMC gene expression in cardiac ACR [8, 31, 32]. Two genes, calgranulin B (S100a9; S100 calcium binding protein A9) and granzyme B (Gzmb) were present on both lists. In rats with ACR, S100a9 was induced 11 fold and Gzmb was induced 3 fold relative to the strain alone effect.
Relatively large expression differences were detected in PBMC between two strains of rats commonly used in models of organ transplantation. Conversely, only a small number of differentially expressed genes in heart tissue were related to rat strain. The larger effect of strain on gene expression in PBMC compared to heart tissue may in part reflect the abundance of strain-specific, self-recognition molecules that are expressed by lymphocytes. As such, strain specifically affected genes involved with the immune response, cell motility, and cell death, functional categories that might be misconstrued as ACR-related. Moreover, the magnitude of the strain effect in PBMC (FC ≥ 3 for 265 probesets) substantially obscured the gene expression signature of rejection. Potential markers specific to ACR could only be identified after measuring and accounting for the strain effect. Similar variability attributable to genotypic heterogeneity has also been documented in human populations [16, 17, 38] and therefore has major implications for experimental design and power calculations in patient biomarker studies.
Approximately 85 to 95% of human genetic variation is attributable to individual heterogeneity within a population while the remaining 5 to 15% can be ascribed to differences between populations [16, 18]. In addition to external influences and epigenetic factors, this background genetic variation contributes to differences in gene expression [15–17] that may add unwanted noise to results from high – throughput methodologies such as microarrays. Genotypic effects in human PBMC were found to significantly alter the expression of more than 300 transcripts . Major histocompatibility complex-associated and interferon-regulated genes were among those most affected by genotype in human PBMC preparations. Investigations performed in inbred animals reduce this source of variability and thereby serve as a "best case" scenario or "proof of principle." However, genetic background may still negatively impact the results and interpretation of animal experiments, a well recognized concern in gene targeting studies . At particular risk are investigations that require hybrid animals or multiple animal strains.
Natural variation in gene expression has been well documented among laboratory strains of fruit flies  and mice [20–22, 40]. Expression profiling of brain [20, 21], spleen , and liver  have determined that 1 to 3% of mouse transcripts are significantly affected by animal strain. In addition to these baseline effects, the gene expression response to seizure was shown to be significantly different comparing the brains of two inbred strains of mice . Even more relevant to immunity and transplant medicine, bone marrow derived macrophages from 5 mouse strains displayed unique transcriptional phenotypes in response to lipopolysaccharide challenges . Allogeneic animal transplant models typically employ two immunologically distinct strains to serve as donor and recipient. Therefore background genotypic effects on transcript abundance have a real potential to confound the search for biomarkers and new therapeutic targets. In the current study, the impact of rat strain on PBMC gene expression was unexpectedly large and primarily affected transcripts associated with the immune response, effects that could be misinterpreted as ACR-related. These results underscore the importance of experimental designs and analytical approaches in expression profiling studies that control for strain effects in animal models and genotypic heterogeneity in patient populations.
Measuring and then adjusting post hoc for large strain effects on gene expression identified 30 genes with the potential to be differentially regulated during rejection in circulating PBMC. A thematic analysis of this list suggested biological plausibility. However, homologues of only two of these genes, S100 calcium binding protein A9 and granzyme B have been previously linked to cardiac rejection in humans [8, 32]. Two S100 like binding proteins, myeloid related protein 8 (MRP8) and MRP14, have been shown to be increased in the serum of patients relatively early in acute renal allograft rejection . Granzyme B has also been found to be over-expressed in the peripheral blood of patients with acute renal allograft rejection . Another potentially rejection-related gene from the current study, high mobility group box 1 (Hmgb1) has been investigated in a previous animal study of acute rejection . In a murine cardiac transplant model, Hmgb1 expression was significantly increased in allogeneic compared to isogeneic transplants. Increased expression of Hmgb1 in allografts was associated with active secretion of Hmgb1 by infiltrating immune cells. Blockade of extracellular Hmgb1 significantly delayed acute allograft rejection .
This study has several limitations. PBMC from transplanted animals differed by both transplant type (isogeneic vs. allogeneic) and animal strain. If strain and ACR interacted in a non-additive manner then the selection of rejection-related genes might have been unreliable. These genes require confirmation using an experimental design that avoids the need for cross strain comparisons. Likewise, it would be prudent to validate any results in more than one rat strain. Robust genes that identify rejection within multiple rat strains might be more likely to serve as reliable biomarkers in patients with their inherent heterogeneity. Another potential limitation of our analysis was the assumption that systemic effects of ACR on native hearts were minimal and that expression differences in native hearts were almost entirely due to strain. Nonetheless, the heart tissue strain effect, examined only in native hearts, was relatively small. Finally, in our study and others, some gene expression differences attributed to ACR in heart tissue may reflect the detection of strain-associated gene expression attributable to recipient lymphocytes that have infiltrated the donor allograft.
Despite these limitations, our results have implications for recent efforts to identify biomarkers of ACR in peripheral blood [8, 31, 32, 44–46]. Human genetic variation has a substantial impact on gene expression independent of exogenous factors and conditions [15–17, 38]. Notably, the influence of genetic variation on transcript abundance appears to be particularly strong in cells of the immune system [17, 38]. Baseline genetic differences between human transplant recipients may make it difficult to identify a universally applicable set of biomarkers for noninvasively detecting acute cellular rejection. Complex interactions between genetic background (polymorphisms), comorbidities, and immunosuppressive regimens may further degrade the performance characteristics of biomarkers in this heterogeneous patient population.
Tissue specific differences in strain between donor and recipient animals can confound gene expression profiles in animal models of ACR. In heart tissue, there is a very modest strain effect which shares little in common with the effects of rejection in transplanted hearts. In PBMC, there is a substantial strain effect in untransplanted animals which shares a great deal in common with the combined effects of strain and rejection in transplanted animals. When performing animal gene expression studies, animal strain effects should be considered and accounted for in the design and analysis of the study. Given the magnitude of strain-related effects in PBMC preparations, the most prudent approach would be to avoid cross-strain comparisons in leukocyte studies of transplant rejection. These findings may also have implications for gene expression studies in diverse, genetically heterogeneous patient populations undergoing transplantation.
The authors would like to thank Adrienne E Hergen for her invaluable technical support; Ms. Zoila Rangel for carrying out the identification of human homologs to rat genes identified in our study using publicly available tools; and Kelly Byrne for her assistance in manuscript preparation and submission.
- Kirklin JK, Naftel DC, Kirklin JW, Blackstone EH: Risk factors for death and related events after cardiac transplantation. Adv Cardiol. 1988, 36: 278-292.View ArticlePubMedGoogle Scholar
- Kirklin JK, Naftel DC, McGiffin DC, McVay RF, Blackstone EH, Karp RB: Analysis of morbid events and risk factors for death after cardiac transplantation. J Am Coll Cardiol. 1988, 11: 917-924.View ArticlePubMedGoogle Scholar
- Miller LW, Schlant RC, Kobashigawa J, Kubo S, Renlund DG: 24th Bethesda conference: Cardiac transplantation. Task Force 5: Complications. J Am Coll Cardiol. 1993, 22: 41-54.View ArticlePubMedGoogle Scholar
- Grossi P, De Maria R, Caroli A, Zaina MS, Minoli L: Infections in heart transplant recipients: the experience of the Italian heart transplantation program. Italian Study Group on Infections in Heart Transplantation. J Heart Lung Transplant. 1992, 11: 847-866.PubMedGoogle Scholar
- Kemkes BM, Schutz A, Engelhardt M, Brandl U, Breuer M: Noninvasive methods of rejection diagnosis after heart transplantation. J Heart Lung Transplant. 1992, 11: S221-231.PubMedGoogle Scholar
- Marboe CC, Billingham M, Eisen H, Deng MC, Baron H, Mehra M, Hunt S, Wohlgemuth J, Mahmood I, Prentice J, Berry G: Nodular endocardial infiltrates (Quilty lesions) cause significant variability in diagnosis of ISHLT Grade 2 and 3A rejection in cardiac allograft recipients. J Heart Lung Transplant. 2005, 24: S219-226. 10.1016/j.healun.2005.04.001.View ArticlePubMedGoogle Scholar
- Halloran PF, Reeve J, Kaplan B: Lies, damn lies, and statistics: the perils of the P value. Am J Transplant. 2006, 6: 10-11. 10.1111/j.1600-6143.2005.01182.x.View ArticlePubMedGoogle Scholar
- Deng MC, Eisen HJ, Mehra MR, Billingham M, Marboe CC, Berry G, Kobashigawa J, Johnson FL, Starling RC, Murali S, et al: Noninvasive discrimination of rejection in cardiac allograft recipients using gene expression profiling. Am J Transplant. 2006, 6: 150-160. 10.1111/j.1600-6143.2005.01175.x.View ArticlePubMedGoogle Scholar
- Saiura A, Mataki C, Murakami T, Umetani M, Wada Y, Kohro T, Aburatani H, Harihara Y, Hamakubo T, Yamaguchi T, et al: A comparison of gene expression in murine cardiac allografts and isografts by means DNA microarray analysis. Transplantation. 2001, 72: 320-329. 10.1097/00007890-200107270-00027.View ArticlePubMedGoogle Scholar
- Erickson LM, Pan F, Ebbs A, Kobayashi M, Jiang H: Microarray-based gene expression profiles of allograft rejection and immunosuppression in the rat heart transplantation model. Transplantation. 2003, 76: 582-588. 10.1097/01.TP.0000081398.65568.1B.View ArticlePubMedGoogle Scholar
- Saiura A, Kohro T, Yamamoto T, Izumi A, Wada Y, Aburatani H, Sugawara Y, Hamakubo T, Taniguchi T, Naito M, et al: Detection of an up-regulation of a group of chemokine genes in murine cardiac allograft in the absence of interferon-gamma by means of DNA microarray. Transplantation. 2002, 73: 1480-1486. 10.1097/00007890-200205150-00019.View ArticlePubMedGoogle Scholar
- Inaki N, Tsunezuka Y, Kawakami K, Sato H, Takino T, Oda M, Watanabe G: Increased matrix metalloproteinase-2 and membrane type 1 matrix metalloproteinase activity and expression in heterotopically transplanted murine tracheas. J Heart Lung Transplant. 2004, 23: 218-227. 10.1016/S1053-2498(03)00112-8.View ArticlePubMedGoogle Scholar
- Yamaguchi Y, Okabe K, Matsumura F, Akizuki E, Matsuda T, Ohshiro H, Liang J, Ishihara K, Mori K, Ogawa M: Expression of the c-kit proto-oncogene in rat hepatic allografts during acute rejection. Hepatology. 1999, 29: 133-139. 10.1002/hep.510290105.View ArticlePubMedGoogle Scholar
- Christopher K, Mueller TF, DeFina R, Liang Y, Zhang J, Gentleman R, Perkins DL: The graft response to transplantation: a gene expression profile analysis. Physiol Genomics. 2003, 15: 52-64.View ArticlePubMedGoogle Scholar
- Morley M, Molony CM, Weber TM, Devlin JL, Ewens KG, Spielman RS, Cheung VG: Genetic analysis of genome-wide variation in human gene expression. Nature. 2004, 430: 743-747. 10.1038/nature02797.PubMed CentralView ArticlePubMedGoogle Scholar
- Storey JD, Madeoy J, Strout JL, Wurfel M, Ronald J, Akey JM: Gene-expression variation within and among human populations. Am J Hum Genet. 2007, 80: 502-509. 10.1086/512017.PubMed CentralView ArticlePubMedGoogle Scholar
- Zhang W, Duan S, Kistner EO, Bleibel WK, Huang RS, Clark TA, Chen TX, Schweitzer AC, Blume JE, Cox NJ, Dolan ME: Evaluation of genetic variation contributing to differences in gene expression between populations. Am J Hum Genet. 2008, 82: 631-640. 10.1016/j.ajhg.2007.12.015.PubMed CentralView ArticlePubMedGoogle Scholar
- Rosenberg NA, Pritchard JK, Weber JL, Cann HM, Kidd KK, Zhivotovsky LA, Feldman MW: Genetic structure of human populations. Science. 2002, 298: 2381-2385. 10.1126/science.1078311.View ArticlePubMedGoogle Scholar
- Rifkin SA, Kim J, White KP: Evolution of gene expression in the Drosophila melanogaster subgroup. Nat Genet. 2003, 33: 138-144. 10.1038/ng1086.View ArticlePubMedGoogle Scholar
- Sandberg R, Yasuda R, Pankratz DG, Carter TA, Del Rio JA, Wodicka L, Mayford M, Lockhart DJ, Barlow C: Regional and strain-specific gene expression mapping in the adult mouse brain. Proc Natl Acad Sci USA. 2000, 97: 11038-11043. 10.1073/pnas.97.20.11038.PubMed CentralView ArticlePubMedGoogle Scholar
- Suzuki Y, Nakayama M: Differential profiles of genes expressed in neonatal brain of 129X1/SvJ and C57BL/6J mice: A database to aid in analyzing DNA microarrays using nonisogenic gene-targeted mice. DNA Res. 2003, 10: 263-275. 10.1093/dnares/10.6.263.View ArticlePubMedGoogle Scholar
- Pritchard C, Coil D, Hawley S, Hsu L, Nelson PS: The contributions of normal variation and genetic background to mammalian gene expression. Genome Biol. 2006, 7: R26-10.1186/gb-2006-7-3-r26.PubMed CentralView ArticlePubMedGoogle Scholar
- Billingham ME, Cary NR, Hammond ME, Kemnitz J, Marboe C, McCallister HA, Snovar DC, Winters GL, Zerbe A: A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection. Heart Rejection Study Group. The International Society for Heart Transplantation. J Heart Transplant. 1990, 9: 587-593.PubMedGoogle Scholar
- Stewart S, Winters GL, Fishbein MC, Tazelaar HD, Kobashigawa J, Abrams J, Andersen CB, Angelini A, Berry GJ, Burke MM, et al: Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant. 2005, 24: 1710-1720. 10.1016/j.healun.2005.03.019.View ArticlePubMedGoogle Scholar
- Yokoyama H, Ohmi M, Murata S, Nakame T, Tabayashi K, Mohri H: Proposal of a working left heart model with a heterotopic transplantation technique in rats. J Heart Lung Transplant. 1995, 14: 706-712.PubMedGoogle Scholar
- Pfaffl MW: A new mathematical model for relative quantification in real-time RT-PCR. Nucleic acids research. 2001, 29: e45-10.1093/nar/29.9.e45.PubMed CentralView ArticlePubMedGoogle Scholar
- Mathematical and Statistical Computing Lab (MSCL) Analysts Toolbox. [http://abs.cit.nih.gov/MSCLtoolbox/]
- Edgar R, Domrachev M, Lash AE: Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic acids research. 2002, 30: 207-210. 10.1093/nar/30.1.207.PubMed CentralView ArticlePubMedGoogle Scholar
- National Center for Biotechnology Information (NCBI) Gene Expression Omnibus (GEO) Accession Viewer. [http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE6342]
- Benjamini Y, Hochberg Y: Controlling the False Discovery Rate: A practical and powerful approach to multiple testing. Journal of the Royal Statistical Society Series B (Methodological). 1995, 57: 289-300.Google Scholar
- Horwitz PA, Tsai EJ, Putt ME, Gilmore JM, Lepore JJ, Parmacek MS, Kao AC, Desai SS, Goldberg LR, Brozena SC, et al: Detection of cardiac allograft rejection and response to immunosuppressive therapy with peripheral blood gene expression. Circulation. 2004, 110: 3815-3821. 10.1161/01.CIR.0000150539.72783.BF.View ArticlePubMedGoogle Scholar
- Schoels M, Dengler TJ, Richter R, Meuer SC, Giese T: Detection of cardiac allograft rejection by real-time PCR analysis of circulating mononuclear cells. Clin Transplant. 2004, 18: 513-517. 10.1111/j.1399-0012.2004.00197.x.View ArticlePubMedGoogle Scholar
- Affymetrix®. [http://www.affymetrix.com]
- National Center for Biotechnology Information (NCBI). [http://www.ncbi.nlm.nih.gov/]
- Ingenuity® Systems Pathway Analysis. [http://www.ingenuity.com/]
- Database for Annotation, Visualization and Integrated Discovery (DAVID). [http://david.abcc.ncifcrf.gov/home.jsp]
- Hosack DA, Dennis G, Sherman BT, Lane HC, Lempicki RA: Identifying biological themes within lists of genes with EASE. Genome Biol. 2003, 4: R70-10.1186/gb-2003-4-10-r70.PubMed CentralView ArticlePubMedGoogle Scholar
- Whitney AR, Diehn M, Popper SJ, Alizadeh AA, Boldrick JC, Relman DA, Brown PO: Individuality and variation in gene expression patterns in human blood. Proc Natl Acad Sci USA. 2003, 100: 1896-1901. 10.1073/pnas.252784499.PubMed CentralView ArticlePubMedGoogle Scholar
- Gerlai R: Gene-targeting studies of mammalian behavior: is it the mutation or the background genotype?. Trends Neurosci. 1996, 19: 177-181. 10.1016/S0166-2236(96)20020-7.View ArticlePubMedGoogle Scholar
- Wells CA, Ravasi T, Faulkner GJ, Carninci P, Okazaki Y, Hayashizaki Y, Sweet M, Wainwright BJ, Hume DA: Genetic control of the innate immune response. BMC Immunol. 2003, 4: 5-10.1186/1471-2172-4-5.PubMed CentralView ArticlePubMedGoogle Scholar
- Burkhardt K, Radespiel-Troger M, Rupprecht HD, Goppelt-Struebe M, Riess R, Renders L, Hauser IA, Kunzendorf U: An increase in myeloid-related protein serum levels precedes acute renal allograft rejection. J Am Soc Nephrol. 2001, 12: 1947-1957.PubMedGoogle Scholar
- Simon T, Opelz G, Wiesel M, Ott RC, Susal C: Serial peripheral blood perforin and granzyme B gene expression measurements for prediction of acute rejection in kidney graft recipients. Am J Transplant. 2003, 3: 1121-1127. 10.1034/j.1600-6143.2003.00187.x.View ArticlePubMedGoogle Scholar
- Huang Y, Yin H, Han J, Huang B, Xu J, Zheng F, Tan Z, Fang M, Rui L, Chen D, et al: Extracellular hmgb1 functions as an innate immune-mediator implicated in murine cardiac allograft acute rejection. Am J Transplant. 2007, 7: 799-808. 10.1111/j.1600-6143.2007.01734.x.View ArticlePubMedGoogle Scholar
- Pham MX, Deng MC, Kfoury AG, Teuteberg JJ, Starling RC, Valantine H: Molecular testing for long-term rejection surveillance in heart transplant recipients: design of the Invasive Monitoring Attenuation Through Gene Expression (IMAGE) trial. J Heart Lung Transplant. 2007, 26: 808-814. 10.1016/j.healun.2007.05.017.View ArticlePubMedGoogle Scholar
- Flechner SM, Kurian SM, Head SR, Sharp SM, Whisenant TC, Zhang J, Chismar JD, Horvath S, Mondala T, Gilmartin T, et al: Kidney transplant rejection and tissue injury by gene profiling of biopsies and peripheral blood lymphocytes. Am J Transplant. 2004, 4: 1475-1489. 10.1111/j.1600-6143.2004.00526.x.PubMed CentralView ArticlePubMedGoogle Scholar
- Starling RC, Pham M, Valantine H, Miller L, Eisen H, Rodriguez ER, Taylor DO, Yamani MH, Kobashigawa J, McCurry K, et al: Molecular testing in the management of cardiac transplant recipients: initial clinical experience. J Heart Lung Transplant. 2006, 25: 1389-1395. 10.1016/j.healun.2006.10.002.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.